We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $178.69, moving +1.33% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.73% for the day. Meanwhile, the Dow gained 0.49%, and the Nasdaq, a tech-heavy index, added 1.19%.
Prior to today's trading, shares of the kidney dialysis provider had lost 2.92% was narrower than the Medical sector's loss of 3.74% and lagged the S&P 500's gain of 0.55%.
The upcoming earnings release of DaVita HealthCare will be of great interest to investors. On that day, DaVita HealthCare is projected to report earnings of $3.78 per share, which would represent year-over-year growth of 50.6%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 billion, up 3.23% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $14.57 per share and a revenue of $14.28 billion, representing changes of +35.16% and +4.67%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for DaVita HealthCare. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DaVita HealthCare presently features a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 12.1. This represents a discount compared to its industry average Forward P/E of 19.68.
One should further note that DVA currently holds a PEG ratio of 0.46. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 1.71 at yesterday's closing price.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 50, which puts it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
DaVita HealthCare (DVA - Free Report) closed the most recent trading day at $178.69, moving +1.33% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.73% for the day. Meanwhile, the Dow gained 0.49%, and the Nasdaq, a tech-heavy index, added 1.19%.
Prior to today's trading, shares of the kidney dialysis provider had lost 2.92% was narrower than the Medical sector's loss of 3.74% and lagged the S&P 500's gain of 0.55%.
The upcoming earnings release of DaVita HealthCare will be of great interest to investors. On that day, DaVita HealthCare is projected to report earnings of $3.78 per share, which would represent year-over-year growth of 50.6%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.53 billion, up 3.23% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $14.57 per share and a revenue of $14.28 billion, representing changes of +35.16% and +4.67%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for DaVita HealthCare. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DaVita HealthCare presently features a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 12.1. This represents a discount compared to its industry average Forward P/E of 19.68.
One should further note that DVA currently holds a PEG ratio of 0.46. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 1.71 at yesterday's closing price.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 50, which puts it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.